{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE296nnn/GSE296681/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":[" Other","Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296681"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"In vivo reprogramming of cytotoxic effector CD8+ T cells via fractalkine-conjugated mRNA LNPs","description":"Selective in vivo reprogramming of cytotoxic effector CD8+ T (Teff) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA LNPs) can specifically target and deliver mRNA to CX3CR1+ Teff cells in vitro and in vivo. In mice, fractalkine-conjugated LNPs target up to 90% of blood and splenic Teff cells, and delivery of IL-2 encoding mRNA to Teff cells enables robust IL-2 secretion. In rhesus macaques, fractalkine-conjugated mRNA LNPs target up to 100% of peripheral blood Teff cells and delivery of CD62L-mRNA enables transient CD62L expression. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA LNPs for effective and efficient transient in vivo modification of Teff cells.","dates":{"publication":"2026/05/21"},"accession":"GSE296681","cross_references":{"GSM":["GSM8974590","GSM8974581","GSM8974580","GSM8974591","GSM8974579","GSM8974583","GSM8974582","GSM8974585","GSM8974584","GSM8974587","GSM8974576","GSM8974586","GSM8974589","GSM8974578","GSM8974577","GSM8974588"],"GPL":["24676"],"GSE":["296681"],"taxon":["Homo sapiens"]}}